Longer Chemo Regimen Offers Better DFS For Premenopausal Breast Cancer
Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable
FDA Approves Gleevec For First Line Rx Of CML
Fragmin Cuts Risk Of VE By 50 Percent In Study
Sirolimus-Containing Therapy Reduces GVHD, Study Finds
Avastin Regimen Bested Chemo Alone In Early Disease
Paraplatin Lengthened TTP In HER2+ Advanced Breast Ca
Study Confirms Cancer Risk Increase Due To Combined HRT
Pill Associated With Cancer In BRCA1 Mutation Carriers
National Cancer Institute Lists Approved Clinical Trials
Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval









